A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Wednesday, October 16, 2013
Stem Cell Research : BrainStorm to Initiate Study for Multiple Sclerosis at Hadassah Medical Center
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--October 15, 2013--
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will initiate a pre-clinical study for Multiple Sclerosis (MS) at the Hebrew University Hadassah Medical Center's SPF-grade animal laboratory in Jerusalem. The study was approved by the Institutional Animal Care and Use Committee (IACUC) of the Hebrew University.
Based on promising pre-clinical data published by the Company's Chief Scientist, Prof. Daniel Offen of Tel Aviv University, BrainStorm will conduct further studies using the Experimental Autoimmune Encephalomyelitis (EAE) animal model to evaluate MS as an additional indication for its NurOwn technology. Professor Dimitrios Karussis and Dr. Ibrahim Kassis, who have published extensively on pre-clinical research using the EAE model, will be the Principal Investigators of the study.
Prof. Karussis, a Key Opinion Leader in the field of MS, is Head of the multi-disciplinary MS Clinic and Center at Hadassah, member of the European Steering Committee for Bone Marrow Transplantation in MS, member of the Executive Board and Scientific Committee of the European School of Neuroimmunology (ESNI), and former board member of the European Council and Committee for Treatment and Research in MS. He has been the Principal Investigator of several multi-national clinical trials in MS conducted by global pharmaceutical companies.
NurOwn is an autologous, adult stem cell therapy technology that induces bone marrow-derived mesenchymal stem cells (MSC) to secrete high levels of neurotrophic factors for protection of existing motor neurons, promotion of motor neuron growth, and re-establishment of nerve-muscle interaction. More information about NurOwn(TM) can be found at http://brainstorm-cell.com/index.php/science-a-technology/-nurown.